Skip to main content
S&P 5007,676.77+0.70%DOW52,361.58+0.28%NASDAQ26,169.38+0.82%BTC$80,129.00+0.25%ETH$2,324.65+0.23%GOLD$4,027.20-0.28%OIL$101.22-0.53%
Smart Investors Daily
SID Premium
Viatris Inc. logo

NASDAQ · VTRS

Viatris Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$18.29

Up+$0.29 (+1.61%)

Updated Oct 27, 2026, 6:09 AM

SID Score

7.2/10

Composite research score

Smart Money

62/100

Neutral

Market cap
13.35B
P/E ratio
-3.66
Dividend yield
2.62%
52-week range
$12.19 – $18.75
Volume
6.06M
Avg. volume
9.37M

Price performance · VTRS

VTRS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

VTRS closed at $18.29 after 21 trading sessions, up 0.11% for the selected period.

Last close
$18.29
Period change
+0.11%
Period low
$17.25
Period high
$18.66
Daily close
View OHLC price history
VTRS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$18.20$18.395$18.11$18.296.06M
Oct 23, 2026$18.33$18.3805$17.86$18.007.22M
Oct 22, 2026$18.45$18.66$18.345$18.485.44M
Oct 21, 2026$18.64$18.695$18.43$18.4510.19M
Oct 20, 2026$18.34$18.685$18.285$18.6514.27M
Oct 19, 2026$18.625$18.7502$18.175$18.2611.53M
Oct 16, 2026$18.20$18.665$18.15$18.6559.42M
Oct 15, 2026$17.75$18.235$17.7001$18.228.39M
Oct 14, 2026$17.27$17.82$17.24$17.448.68M
Oct 13, 2026$17.66$17.66$17.205$17.257.55M
Oct 12, 2026$17.70$17.79$17.525$17.547.55M
Oct 9, 2026$17.36$17.755$17.185$17.648.83M
Oct 8, 2026$17.26$17.52$16.89$17.4414.11M
Oct 7, 2026$17.52$17.815$17.41$17.497.54M
Oct 6, 2026$17.77$17.87$17.31$17.546.68M
Oct 5, 2026$17.82$17.91$17.45$17.626.36M
Oct 2, 2026$17.53$17.65$17.34$17.607.53M
Oct 1, 2026$17.62$17.835$17.43$17.469.04M
Sep 30, 2026$18.16$18.17$17.71$17.7211.81M
Sep 29, 2026$18.25$18.43$17.865$18.1213.86M
Sep 28, 2026$17.75$18.37$17.5406$18.2712.38M

Latest VTRS news

The latest Smart Investors Daily articles mentioning VTRS.

Stock researchCompany · Overview

VTRS research

Overview

Company profile and research snapshot.

Company profile

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$15.00
Implied upside
—
Analysts
17
VTRS recent ratings
DateFirmRatingTarget
Oct 21, 2026JP MorganNeutral—
Oct 5, 2026UBSBuy—
Sep 23, 2026OppenheimerOutperform—
Sep 16, 2026Piper SandlerNeutral—
Sep 9, 2026Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal Framing

The latest update on Pacira BioSciences lifts the modelled fair value from US$30.00 to about US$33.57 per share, a mid single digit change that reframes where some analysts see the stock settling. With coverage now centered on the agreed US$36.50 per share cash acquisition by Viatris and the question of any remaining upside to that deal price, this new target range helps anchor how research desks are talking about potential outcomes. As you read on, you will see how to track this evolving...

Yahoo · Oct 19, 2026

Viatris’ Dividend Has Room to Grow, but Will Management Deliver?

Viatris Inc. (NASDAQ:VTRS) is a familiar name in the pharmaceutical industry, with a portfolio that stretches from branded medications to generics and fresh, innovative therapies. Its broad reach and diverse lineup help bring in steady revenue year after year. Still, the company faces heavy competition, persistent price pressures, and the ongoing risk of losing exclusivity […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By